Hello. This lesson continues the acute-treatment part of the course. Triptans and common pain medicines help many people, but they may not work well enough, may cause troublesome effects, or may be unsuitable because of other health conditions. Gepants and ditans offer different ways to treat an attack. You will learn where they fit, what to check before using them, and why the driving rule for the ditan lasmiditan is unusually important.
Two ways to interrupt an attack
Both gepants and ditans are acute treatments: they are taken to relieve a migraine attack, rather than simply to reduce the number of attacks over the coming months. Neither is automatically a better choice than a triptan. The useful question is which option offers a reasonable balance of relief, safety, and practicality for a particular person.
Watch this short explanation of their distinct targets:
Rescue Medications for Migraine Attacks
In “Rescue Medications for Migraine Attacks,” Nucleus Medical Media contrasts gepants with lasmiditan, the ditan discussed in this lesson. Watch for the distinction between acting on migraine-related nerve signaling and narrowing blood vessels.
Watch the gepant explanation, followed by lasmiditan and driving. The final seconds begin to move on to another drug class; the key point here is lasmiditan’s eight-hour driving restriction.
During a migraine attack, nerve pathways can release CGRP (calcitonin gene-related peptide), a signaling molecule involved in migraine pain. Gepants block CGRP receptors, making it harder for CGRP to activate that signaling. They do not rely on the blood-vessel narrowing associated with triptans.

Ditans take a different route. Lasmiditan acts selectively at a serotonin receptor called 5-HT1F on migraine-related nerve pathways. Like triptans, it targets signaling involved in an attack, but it does not produce the same triptan-like blood-vessel constriction. That difference can matter when a clinician considers a triptan unsuitable because of cardiovascular or cerebrovascular disease. It does not mean lasmiditan is free of other important risks.
The American Migraine Foundation’s account adds clinical context to this comparison. Its discussion dates from 2020: use its description of the acute-treatment roles and mechanisms, but do not treat its older statements about which gepants are approved only for as-needed use as a current list. Some gepants now also have preventive uses under different schedules.
Gepants and Ditans Therapies | American Migraine Foundation
Read the American Migraine Foundation’s explanation of why these options may be considered when other acute medicines cause problems, then its comparison of ditans with triptans.
Under “Dr. Jessica Ailani explains how new therapies differ from migraine treatments on the market,” read the acute-use description. In “How gepants differ from monoclonal CGRP antibodies (anti-CGRPs),” read the receptor explanation. Then go to “How ditans differ from triptans” and read the clinical comparison, ending with the example of nighttime attacks. Focus on why a clinician might consider a ditan, alongside the limitation imposed by sedation.
Choosing an acute option without overlooking delivery
A gepant may be worth discussing when a triptan is ineffective, poorly tolerated, or unsuitable because its blood-vessel effects are a concern. Acute-use examples include ubrogepant and rimegepant; zavegepant is a nasal option where available. Gepants are not interchangeable in every detail: their approved uses, formulations, and interaction instructions differ. A medicine’s ending is a clue to its class, not a substitute for checking the particular product.
A ditan, currently represented here by lasmiditan, can also be considered when triptans are unsuitable or have not helped. Its lack of triptan-like vasoconstriction is one advantage in that discussion. Its central-nervous-system effects are the counterweight: dizziness and sleepiness can make it impractical even when it might relieve the migraine.
Timing and delivery matter as well as drug class. Acute medicine is generally most useful when taken promptly after recognizing an attack, according to the prescribed instructions. If nausea or vomiting makes swallowing or keeping down a tablet difficult, that is information to bring to the clinician. A dissolvable tablet is still largely swallowed and absorbed through the digestive tract; it is not the same as a non-oral treatment. A nasal formulation may be relevant, depending on availability and suitability.
Consider two treatment discussions. Someone who gets good relief from a triptan but cannot tolerate its adverse effects might discuss a gepant as a different acute strategy. Someone for whom a clinician advises against triptans because of vascular disease might discuss either a gepant or lasmiditan. If that second person must drive soon after treating an attack, lasmiditan’s driving restriction could make it a poor practical fit. The condition, existing medicines, and daily demands all affect the choice.
Interaction checks and lasmiditan’s eight-hour rule
Before starting a gepant or lasmiditan, the prescriber or pharmacist needs a complete medication list. That includes prescriptions, over-the-counter medicines, supplements, and relevant foods or drinks. The aim is not for you to memorize an interaction list; it is to identify what needs checking against the specific medicine proposed.
For several gepants, drugs that affect liver enzymes or transport proteins can change gepant exposure. Examples worth flagging include certain antibiotics and antifungals, some seizure medicines, and rifampin. Grapefruit and supplements such as St. John’s wort can also be relevant. An interaction does not have one universal response across the class: depending on the gepant and the other substance, the clinician may adjust the plan or choose something else. Do not stop or change another prescribed medicine merely to make a gepant possible without clinical advice.
For lasmiditan, medicines or alcohol that cause drowsiness can intensify impairment. Medicines that lower heart rate, such as propranolol, warrant a check too. A clinician should also review other medicines that affect serotonin. The interaction review matters even when each medicine is taken for a different condition.
Read the interaction guidance with that product-specific approach in mind:
Migraine Drug Interactions FAQ | American Migraine Foundation
The American Migraine Foundation’s FAQ gives concrete examples of why an interaction check is part of choosing an acute medicine. Read the examples as prompts for a pharmacist or clinician to check—not as a rule that every named substance has the same effect with every gepant.
In “What medications interact with lasmiditan (Reyvow®)?”, begin at the paragraph describing lasmiditan as an acute medicine and read the safety examples, through the sentence about heart-rate-lowering medicine. Then, in “What medications interact with gepants?”, start at the paragraph naming ubrogepant and rimegepant and read the interaction discussion, ending with the supplements paragraph. Notice the range of substances to disclose; leave decisions about a particular combination or dose to the product-specific review.
Lasmiditan has a clear rule that cannot be replaced by a personal judgment of alertness: do not drive or operate machinery for at least eight hours after a dose, even if you feel capable of doing so. If an attack might occur when driving within that period is unavoidable, tell the prescriber before relying on lasmiditan as the acute plan. Sleepiness may be greater with alcohol or other sedating medicines.
Finally, a different acute option is not a reason to ignore frequent attacks. Gepants have not shown the same established medication-overuse-headache risk as some older acute medicines, but needing treatment often still merits a review of migraine burden and whether prevention should be discussed. The next lesson examines medication-use records and medication-overuse headache in detail.
Key takeaways
Gepants block CGRP signaling; lasmiditan acts on a serotonin receptor on migraine-related nerve pathways. Both can provide acute options when more familiar medicines are ineffective or unsuitable, without relying on triptan-like blood-vessel narrowing. The choice still depends on formulation, other medicines, health conditions, and daily activities. In particular, check gepant interactions against the exact product, and plan around no driving or machinery for eight hours after lasmiditan.